¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Clinical Trials Data Monitoring Committees"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® fetal monitoring ÇÑ±Û Å¾ư¨½Ã
¼³¸í   
  ÀӽŠÁßÀ̳ª ºÐ¸¸ ÁßÀǠžÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ» Å¾ư¨½Ã¶ó°í ÇÑ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ Àִµ¥ Å©°Ô ºÐ¸¸Àü Å¾ư¨½Ã¿Í ºÐ¸¸Áߠžư¨½Ã·Î Å©°Ô ³ª´«´Ù.
  
  1. ºÐ¸¸Àü Å¾ư¨½Ã´Â ºÐ¸¸Çϱâ ÀÌÀüÀǠžÆÀÇ »óŸ¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î ´ÙÀ½°ú °°Àº ¿©·¯ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù.
  
    1)¾ç¼öõÀÚ-ÁÖ»ç±â¸¦ ÀÌ¿ëÇØ¼­ »ê¸ðÀÇ ¹è¸¦ ÅëÇØ¼­ ¾ç¼ö¸¦ ¾ò¾î¼­ ºÐ¼®ÇÏ¿© Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â ¹æ¹ý. ÀӽŠ15ÁÖ À̻󿡼­ ½Ç½ÃÇÒ ¼ö°¡ ÀÖ´Ù.
  
    2)ÅÈÁÙõÀÚ-ÃÊÀ½ÆÄ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ¿µ»óÀ» º¸¸é¼­ ÅÈÁÙ¼Ó¿¡ ¹Ù´ÃÀ» ³Ö¾î¼­ ±×°÷ÀÇ Ç÷°üÀ» Ã£¾Æ Ç÷¾×À» Ã¤ÃëÇÏ¿© °Ë»çÇϴ ¹æ¹ý.
  
    3)½ºÆ®·¹½º°Ë»ç-žƵµ Àڱüӿ¡¼­ ¿îµ¿À» ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î Å¾ư¡ Àڱüӿ¡¼­ ¿îµ¿À» ÇÒ °æ¿ì¿¡´Â Å¾ÆÀÇ ½ÉÀå ¹Úµ¿ÀÌ »¡¶óÁö°Ô µÈ´Ù. Å¾ÆÀÇ ¿îµ¿°ú Å¾ÆÀÇ ½ÉÀå¹Úµ¿À» µ¿½Ã¿¡ °¨½ÃÇÏ¿© ¿îµ¿½Ã¿¡ Å¾ÆÀÇ ½ÉÀå¹Úµ¿ÀÌ »¡¶óÁö´Â °¡¸¦ ¾Ë¾Æº¸´Â °ÍÀÌ´Ù.
  
    4)žÆÃ»°¢Àڱذ˻ç-30ÁÖ ÀÌ»óÀÌ µÈ Å¾ƴ ¼Ò¸®ÀÇ Àڱؿ¡ ´ëÇØ¼­ ¹ÝÀÀÀ» ÇÑ´Ù. Áï ¼Ò¸®¸¦ µé·ÁÁÖ¾úÀ» °æ¿ì¿¡ Å¾ư¡ ¹ÝÀÀÀ» Çؼ­ ½ÉÀåÀÇ ¹Úµ¿¼ö°¡ Áõ°¡¸¦ ÇÑ´Ù.
  
    5)¼öÃེƮ·¹½º°Ë»ç-Á¤»óÀûÀΠžƴ ÀÚ±ÃÀÌ ¼öÃàÇϸé ÀÌ¿¡ ¹ÝÀÀÀ» Çؼ­ ½É¹Ú¼ö°¡ º¯È­ÇÑ´Ù. À̰ÍÀ» ÀÌ¿ëÇÏ¿© Å¾ÆÀÇ »óŸ¦ °Ë»çÇϴ ¹æ¹ýÀÌ´Ù.
  
  2. ºÐ¸¸Áߠžư¨½Ã
  
  ºÐ¸¸µµÁß¿¡ Å¾ÆÀÇ °Ç°­»óŸ¦ °¨½ÃÇϴ °ÍÀÌ´Ù. ´ëü·Î ºÐ¸¸µµÁß¿¡ Å¾ư¡ Àú»ê¼ÒÁõÀ̳ª ¿©·¯ °¡Áö Ãæ°ÝÀ» ¹Þ´Â °æ¿ì°¡ ¸¹À¸¹Ç·Î ºÐ¸¸µµÁßÀǠžư¨½Ã´Â Áß¿äÇÑ Àǹ̸¦ °¡Áø´Ù.
  
    1)ÀüÀڽĞư¨½Ã-Àü±âÀû ÀåÄ¡¸¦ ÀÌ¿ëÇÏ¿© Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ¸·Î °¨½ÃÀÇ ´ë»óÀº ÀÚ±ÃÀÇ ¼öÃà°ú Å¾ÆÀÇ ½ÉÀå¹Úµ¿¼öÀÌ´Ù.
  
    2)žƸӸ®µ¤°³ Ç¥º»Ã¤Ãë Ç÷¾×-ºÐ¸¸µµÁß¿¡ Å¾ÆÀÇ µÎÇÇÀÇ Ç÷°ü¿¡¼­ Ç÷¾×À» Ã¤ÃëÇÏ¿© °Ë»ç¸¦ ÅëÇØ¼­ Å¾ÆÀÇ »óŸ¦ ¾Æ´Â ¹æ¹ýÀÌ´Ù. ÁַΠ°Ë»ç¸¦ ÇàÇϴ Á¾¸ñÀº Ç÷¾×ÀÇ pHÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • data
    ÀÚ·á
  • data acquisition
    ÀÚ·á¼öÁý
  • data clipping
    ÀÚ·áÀý´Ü
  • data clipping artifact
    ÀÚ·áÀý´ÜÀΰø¹°
  • data display
    ÀÚ·áÇ¥½Ã
  • data processing
    ÀÚ·áó¸®
  • material safety data sheet
    ¹°Áú¾ÈÀüÀÚ·á¿ëÁö
  • area monitoring
    ±¸¿ª°¨½Ã
  • air monitoring
    ´ë±â°¨½Ã
  • blood glucose monitoring
    Ç÷´ç°¨½Ã
  • central venous pressure monitoring
    Áß½ÉÁ¤¸Æ¾Ð°¨½Ã
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • fetal monitoring
    žư¨½Ã, žƸð´ÏÅ͸µ
  • hemodynamic monitoring
    Ç÷¿ªÇа¨½Ã, Ç÷¿ªÇиð´ÏÅ͸µ
  • invasive monitoring
    ħ½À°¨½Ã
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • data
    ÀÚ·á
  • baseline data
    ±âÃÊÀÚ·á
  • monitoring
    °¨½Ã
  • therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ°¨½Ã
  • clinical
    Áø·á-. ÀÓ»ó-
  • objective structured clinical (OSCE) examination
    °´°ü±¸Á¶È­Áø·á½ÃÇè
  • clinical manifestation
    ÀÓ»óÁõ»ó, ÀÓ»ó¼Ò°ß
  • clinical trial
    ÀÓ»ó½ÃÇè
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • clinical data
    ÀÓ»óÀÚ·á
  • data acquisition
    ÀÚ·á¼öÁý
  • data clipping artifact
    ÀÚ·áÀý´ÜÀΰø¹°
  • baseline data
    ±âÃÊÀÚ·á
  • blood gas data
    Ç÷¾×°¡½º°Ë»çÀÚ·á
  • data clipping
    ÀÚ·áÀý´Ü
  • data
    ÀÚ·á, Àç·á, µ¥ÀÌÅÍ
  • data display
    ÀÚ·áÇ¥½Ã
  • data processing
    ÀÚ·áó¸®
  • discrete data
    ÀÌ»êÀÚ·á
  • surveillance data
    °ü¸®Á¤º¸Á¶»çÀÚ·á
  • material safety data sheet
    ¹°Áú¾ÈÀüÀÚ·á¿ëÁö
  • air monitoring
    ´ë±â°¨½Ã
  • area monitoring
    ±¸¿ª°¨½Ã
  • central venous pressure monitoring
    Áß½ÉÁ¤¸Æ¾Ð°¨½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Clinical data
    ÀÓ»óÀÚ·á
  • Data analysis
    Á¤º¸ºÐ¼®
  • MSDS => Material Safety Data Sheet
    ¹°Áú¾ÈÀüÀÚ·á¿ëÁö
  • identifying data
    ½Å»óÀÚ·á
  • Clinical skills
    ÀÓ»ó¼ú±â
  • GCP : good clinical practice
    ÀÓ»ó½ÃÇè °ü¸®±âÁØ.
  • Good Clinical Practice(GCP)
    ÀǾàǰ ÀÓ»ó½ÃÇè °ü¸®±âÁØ
  • SCAG, Sandoz Clinical Assessment-Geriatric
    »êµµ½º ³ëÀÎÀÓ»óÆò°¡(-ôµµ)
  • SCAN, Schedule for Clinical Assessment in Neuropsychaitry
    ½Å°æÁ¤½Å°ú¿¡ ÀÖ¾î ÀÓ»óÆò°¡¸¦ À§ÇÑ ¸ñ·Ï
  • randomized clinical trial
    ¹«ÀÛÀ§ÀÓ»ó½ÇÇè
  • TDM : therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ ¸ð´ÏÅ͸µ.
  • air monitoring
    ´ë±â¿À¿°°¨½Ã(ËÀË»ËçËç˧Ëà).
  • area monitoring
    ±¸¿ª<¹æ»çÇÇÆø>°¨½Ã.
  • glucose monitoring
    Æ÷µµ´ç°¨½Ã
  • heparin therapy monitoring
    ÇìÆÄ¸°¿ä¹ý<--Ä¡·á>°¨½Ã
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • base line data
    ±âÃÊÀÚ·á.
  • data acquisition
    µ¥ÀÌÅͼöÁý
  • data acquisition time
    ÀÚ·á ȹµæ ½Ã°£
  • data archiving
    µ¥ÀÌÅÍÀúÀå
  • data clipping
    ÀÚ·á Àý´Ü
  • data clipping artifact
    ÀÚ·á Àý´Ü Àΰø¹°
  • data collection
    µ¥ÀÌŸ¼öÁý
  • data display
    µ¥ÀÌÅÍÇ¥½Ã
  • data processing
    µ¥ÀÌÅÍó¸®
  • enumeration data
    °è¼ö(Ë­Ëà)µ¥ÀÌŸ.
  • epidemiological data
    ¿ªÇÐÀû ÀÚ·á.
  • identifying data
    ½Å»óÀÚ·á
  • medical data processing computer
    ÀÇ¿ë <µ¥ÀÌÅÍ󸮿ë>Àü<ÀÚ°è>»ê±â(ËöËí<ÊÙ̧ËöËí>Ëø<ËöË­>Ë×Ë»), ÀÇÇÐÀÚ·á󸮿ë ÄÄÇ»ÅÍ.
  • missing data
    °áÃøÄ¡(˭̬̬).
  • paucity of data
    ÀÚ·áºÒÃæºÐ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Clinical crown
    ÀÓ»óÄ¡¾Æ¸Ó¸®
    [¿¾ ¿ë¾î] ÀÓ»óÄ¡°ü
  • Clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®
    [¿¾ ¿ë¾î] ÀÓ»óÄ¡±Ù
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • clinical parasitology
    ÀÓ»ó±â»ýÃæÇÐ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • selected ion monitoring
    ¼±ÅÃ(àÔ÷É) À̿ ¸ð´ÏÅ͹ý(Ûö)
  • single-ion monitoring
    ´Ü(Ó¤)À̿ ¸ð´ÏÅ͸µ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • clinical application
    ÀÓ»óÀû¿ë
  • monitoring
    °¨½Ã
  • personal monitoring
    °³ÀÎ(ÇÇÆø)°¨½Ã
  • data acquisition time
    ÀÚ·áȹµæ½Ã°£
  • data clipping
    ÀÚ·áÀý´Ü
  • data clipping artifact
    ÀÚ·áÀý´ÜÀΰø¹°
  • fiber distributed data interface(FDDI)
    ±¤³×Æ®¿öÅ©
  • multiinstitutional data
    ´Ù±â°üÀÚ·á
  • raw data
    ±âÃÊ ÀÚ·á, »ýÀÚ·á
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AIDSDRUGS clinical trials of acquired immunodeficiency drugs [MEDLARS data base]
AIDSTRIALS clinical trials of acquired immunodeficiency syndrome drugs [MEDLARS data base]
MDS Master of Dental Surgery; maternal deprivation syndrome; medical data screening; medical data system...
CTN calcitonin; clinical trials notification; computer tomography number; continuous noise
CTS carpal tunnel syndrome; clinical trials support [program]; composite treatment score; computed tomog...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACTG AIDS Clinical Trials Group
CCTs Controlled clinical trials
PACTG Paediatric AIDS Clinical Trials Group
RCT Randomized controlled clinical trials
BI-RADS Breast Imaging Reporting And Data System
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ambulatory ventricular function monitoring
    º¸Çà ½Ã ½É½Ç±â´É °¨½Ã
  • length monitoring system
    ±æÀÌ °¨Áö°è
  • monitoring device
    °¨½Ã ÀåÄ¡
  • monitoring instrument
    °¨½Ã ±â±¸
  • data processing
    ÀÚ·á ó¸®
  • digital data
    ¼öÄ¡ ÀÚ·á
  • fiber distributed data interface
    ±¤ ³×Æ®¿öÅ©
  • missing data
    °áÃøÄ¡
  • raw data
    ¿ø ÀÚ·á
  • clinical application
    ÀÓ»óÀû Àû¿ë
  • clinical chart
    º´»ó ÀÏÁö
  • clinical cytogenetics
    ¼¼Æ÷ À¯ÀüÇÐ
    À¯Àü, Áï ¿°»öü¿Í °ü°èµÈ ¼¼Æ÷ ¿ä¼Ò¸¦ ¿¬±¸ÇÏ´Â À¯ÀüÇÐÀÇ ºÐ¾ß.
  • clinical diagnosis
    ÀÓ»ó Áø´Ü, ÀÓ»óÀû Áø´Ü
    Áø´ÜÀº º¸Åë º´·ÂÀ» ûÃëÇÏ°í ½ÅüÀû ¼Ò°ßÀ» ÃëÇϸç Çʿ信 µû¶ó¼­ °Ë»çÇÏ°í ¾òÀº Á¤º¸¸¦ Á¾ÇÕÇØ¼­ ³»·ÁÁö´Â °ÍÀ¸·Î ÀÌ¿Í °°Àº Áø´ÜÀ» ¼ö¼ú ½Ã¿¡ È®ÀÎÇÑ ¼ö¼ú½Ã Áø´Ü, ¶Ç´Â »çÈÄ ºÎ°Ë¿¡ ÀÇÇØ¼­ È®ÀÎµÈ º´¸® Áø´ÜÀ» ´ëºñ½ÃÄѼ­ ÀÓ»ó Áø´ÜÀ̶ó°í ÇÑ´Ù.
  • clinical examination
    ÀÓ»ó °Ë»ç, ÀÓ»ó ÁøÂû, ÀÓ»óÀû °üÂû
  • clinical hematology
    ÀÓ»ó Ç÷¾×ÇÐ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
clinical research trials Evaluating the safety and effectiveness of medications or medical devices by monitoring their effects on large groups of people. Clinical medical trials sponsored by the U. S. Government are listed on a web site of the National Institutes of Health (NIH). The NIH Clinical Centre intends to make details of current clinical research studies for various diseases available over the Internet to increase opportunities for patients and physicians to participate in clinical investigations.
(12 Dec 1998)
clinical trials Medical research studies conducted with volunteers. Each study is designed to answer scientific questions and to find better ways to prevent, detect, or treat cancer.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
controlled clinical trials Clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterised as randomised controlled trials. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are simply designated as controlled clinical trials.
(12 Dec 1998)
professional staff committees Committees of professional personnel who have responsibility for determining policies, procedures, and controls related to professional matters in health facilities.
(12 Dec 1998)
ethics committees Committees whose purpose may be to direct educational programs; to provide forums for discussion of ethical issues among hospital or medical professionals and others; to serve in an advisory capacity and/or as a resource to health professionals involved in biomedical decision making; or to review and evaluate institutional experiences related to decisions having biomedical ethical implications.
(12 Dec 1998)
randomised controlled trials Clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and trials employing any of these techniques for patient assignment are designated simply controlled clinical trials.
(12 Dec 1998)
automatic data processing Data processing largely performed by automatic means.
(12 Dec 1998)
Physicians Data Query <oncology> A free enquiry service originating in the USA for physicians on all state of the art cancer diagnostic, preventive and treatment methods.
The documents are provided by the US National Cancer Institute and includes electronic access of various forms.
WWW: CancerNET
Acronym: PDQ
(12 Jan 1998)
molecular sequence data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as genbank, european molecular biology laboratory (embl), national biomedical research foundation (nbrf), or other sequence repositories.
(12 Dec 1998)
national practitioner data bank A databank established by the health care quality improvement act of 1986 authorizing the department of health and human services to collect and release information on the professional competence and conduct of physicians, dentists, nurses, and other health care practitioners. The data include adverse actions on physicians' malpractice, licensure, hospital privileges, concealing of pertinent information, and the like.
(12 Dec 1998)
subjective assessment data Those facts that are observable and measurable by the nurse.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Clinical Trials Data Monitoring Committees - »õâ Committees established to review interim data and efficacy outcomes in CLINICAL TRIALS. The findings of these committees are used in deciding whether a trial should be continued as designed, changed, or terminated. Government regulations regarding federally-funded research involving human subjects (the "Common Rule") require (45 CFR 46.111) that research ethics committees reviewing large-scale clinical trials monitor the data collected using a mechanism such as a data monitoring committee. FDA regulations (21 CFR 50.24) require that such committees be established to monitor studies conducted in emergency settings.
    Synonyms : Data Monitoring Committees, Board, Safety Monitoring, Boards, Safety Monitoring, Committee, Data Monitoring, Committees, Data Monitoring, Data Monitoring Committee, Monitoring Board, Safety, Monitoring Boards, Safety, Monitoring Committee, Data
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Nuremberg trials
    ´µ¸¥º£¸£Å© ÀçÆÇ(³ªÄ¡½º Àü¹ü¿¡ ´ëÇÑ(1945-46))
  • radio monitoring
    ÀüÆÄ °¨½Ã
  • clinical
    ÀÓ»óÀÇ
  • clinical
    ÀÓ»óÀÇ;º´»óÀÇ;º´½Ç¿ëÀÇ;(ÆÇ´Ü.¹¦»çµîÀÌ ±Øµµ·Î)°´°üÀûÀÎ;ºÐ¼®ÀûÀÎ;³ÃÁ¤ÇÑ;º´»ó(ÀÓÁ¾)ÀÇ (¼¼·Ê);~ly ÀÓ»óÀûÀ¸·Î
  • clinical death
    ÀÓ»ó»ç(±â±â¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í ÀÓ»óÀû °üÂû·Î ÆÇ´ÜÇÑ Á×À½)
  • clinical ecologist
    ÀÓ»ó »ýÅÂÇÐÀÚ
  • clinical ecology
    ÀÓ»ó »ýÅÂÇÐ
  • clinical pathology
    ÀÓ»ó º´¸®ÇÐ
  • clinical pharmacology
    ÀÓ»ó ¾àÇÐ
  • clinical psychology
    ÀÓ»ó ½É¸®ÇÐ
  • automatic data processing
    ÀÚµ¿ Á¤º¸ ó¸®
  • data
    Àç·á;ÀÚ·á;µ¥ÀÌÅÍ
  • data acquisition
    (Àü»ê)µ¥ÀÌÅÍ ¼öÁý
  • data bank
    µ¥ÀÌÅ͹ðÅ©¿¡ ³Ö´Ù(º¸°üÇÏ´Ù)
  • data bank
    µ¥ÀÌÅÍ ¹ðÅ©(ÀüÀÚ °è»ê±â¿ë Á¤º¸¿Í ±× ÃàÀû º¸°ü ¹× Á¦°ø ±â°ü) ?,
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á